PMID- 21782505
OWN - NLM
STAT- MEDLINE
DCOM- 20120402
LR  - 20181201
IS  - 1873-5967 (Electronic)
IS  - 1386-6532 (Linking)
VI  - 52
IP  - 3
DP  - 2011 Nov
TI  - Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections.
PG  - 164-71
LID - 10.1016/j.jcv.2011.06.008 [doi]
AB  - Human herpesvirus 6 (HHV-6) is a ubiquitous virus inducing a life-long latent 
      infection of its human host. Acute infections (AIs) have been recognized as the 
      cause of severe diseases. These AIs correspond to primary infections (PIs), 
      mainly occurring in young children, endogenous reactivations (ENRs), observed at 
      any age, and putative exogenous reinfections (EXRs). The diagnosis of AIs is now 
      essentially based on the quantification of viral load in bodily fluids and organs 
      by means of real time PCR. However, this diagnosis is currently bothered by the 
      lack of well established viral load thresholds for the different levels of virus 
      replication, the concomitant infection with the two variants HHV-6A and HHV-6B, 
      and the existence, albeit at low frequency, of chromosomal integration of viral 
      DNA. An additional challenge is the difficulty to establish the causality 
      relationship between AI and disease. Although many AIs are asymptomatic or poorly 
      symptomatic with a spontaneous favourable outcome, some have been credited with 
      serious clinical manifestations affecting central nervous system, liver, 
      gastrointestinal tract, lungs, and bone marrow. The main favouring factor for 
      such serious diseases is cellular immune deficiency. These severe diseases can be 
      exemplified by encephalitis cases either associated with PI in young children or 
      with ENR, especially in haematopoietic stem cell transplant recipients. The 
      antiviral drugs ganciclovir, foscarnet and cidofovir have proven to be efficient 
      against AIs and related diseases but the indications and conditions of their use 
      are not yet formally approved. This emphasizes the need for controlled studies 
      addressing both the clinical impact and therapy of HHV-6 AIs.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Agut, Henri
AU  - Agut H
AD  - UPMC Univ Paris 06, ER1 Dynamique, Epidemiologie et Traitement des Infections 
      virales, 75013 Paris, France. henri.agut@psl.aphp.fr
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110722
PL  - Netherlands
TA  - J Clin Virol
JT  - Journal of clinical virology : the official publication of the Pan American 
      Society for Clinical Virology
JID - 9815671
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 0 (Organophosphonates)
RN  - 364P9RVW4X (Foscarnet)
RN  - 8J337D1HZY (Cytosine)
RN  - JIL713Q00N (Cidofovir)
RN  - P9G3CKZ4P5 (Ganciclovir)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cidofovir
MH  - Cytosine/analogs & derivatives/pharmacology/therapeutic use
MH  - DNA, Viral/analysis/genetics
MH  - Foscarnet/pharmacology/therapeutic use
MH  - Ganciclovir/pharmacology/therapeutic use
MH  - Herpesvirus 6, Human/genetics/*pathogenicity
MH  - Humans
MH  - Immunity, Cellular
MH  - Infant
MH  - Organophosphonates/pharmacology/therapeutic use
MH  - *Roseolovirus Infections/diagnosis/drug therapy/virology
MH  - Viral Load
MH  - Virus Latency
EDAT- 2011/07/26 06:00
MHDA- 2012/04/03 06:00
CRDT- 2011/07/26 06:00
PHST- 2011/03/21 00:00 [received]
PHST- 2011/06/09 00:00 [revised]
PHST- 2011/06/24 00:00 [accepted]
PHST- 2011/07/26 06:00 [entrez]
PHST- 2011/07/26 06:00 [pubmed]
PHST- 2012/04/03 06:00 [medline]
AID - S1386-6532(11)00256-3 [pii]
AID - 10.1016/j.jcv.2011.06.008 [doi]
PST - ppublish
SO  - J Clin Virol. 2011 Nov;52(3):164-71. doi: 10.1016/j.jcv.2011.06.008. Epub 2011 
      Jul 22.